These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1269 related articles for article (PubMed ID: 32146606)

  • 1. Development of oncolytic virotherapy: from genetic modification to combination therapy.
    Lan Q; Xia S; Wang Q; Xu W; Huang H; Jiang S; Lu L
    Front Med; 2020 Apr; 14(2):160-184. PubMed ID: 32146606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas.
    Zeng J; Li X; Sander M; Zhang H; Yan G; Lin Y
    Front Immunol; 2021; 12():721830. PubMed ID: 34675919
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic viruses and their application to cancer immunotherapy.
    Chiocca EA; Rabkin SD
    Cancer Immunol Res; 2014 Apr; 2(4):295-300. PubMed ID: 24764576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic virotherapy evolved into the fourth generation as tumor immunotherapy.
    Wang X; Shen Y; Wan X; Hu X; Cai WQ; Wu Z; Xin Q; Liu X; Gui J; Xin HY; Xin HW
    J Transl Med; 2023 Jul; 21(1):500. PubMed ID: 37491263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.
    Shi T; Song X; Wang Y; Liu F; Wei J
    Front Immunol; 2020; 11():683. PubMed ID: 32411132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic Virus-Driven Biotherapies from Bench to Bedside.
    Duan S; Wang S; Qiao L; Yu X; Wang N; Chen L; Zhang X; Zhao X; Liu H; Wang T; Wu Y; Li N; Liu F
    Small; 2023 Jun; 19(23):e2206948. PubMed ID: 36879416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic modification of oncolytic viruses to enhance antitumor immunity.
    Davola ME; Vito A; Wei J; El-Sayes N; Workenhe S; Mossman KL
    Methods Enzymol; 2020; 635():231-250. PubMed ID: 32122548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IL-21 arming potentiates the anti-tumor activity of an oncolytic vaccinia virus in monotherapy and combination therapy.
    Chen T; Ding X; Liao Q; Gao N; Chen Y; Zhao C; Zhang X; Xu J
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33504576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
    Rojas JJ; Sampath P; Hou W; Thorne SH
    Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of oncolytic virus in tumor therapy.
    Huang Z; Guo H; Lin L; Li S; Yang Y; Han Y; Huang W; Yang J
    J Med Virol; 2023 Apr; 95(4):e28729. PubMed ID: 37185868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updates to the antitumor mechanism of oncolytic virus.
    Bai Y; Hui P; Du X; Su X
    Thorac Cancer; 2019 May; 10(5):1031-1035. PubMed ID: 30900824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic viruses and immunity.
    Chaurasiya S; Chen NG; Fong Y
    Curr Opin Immunol; 2018 Apr; 51():83-90. PubMed ID: 29550660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineering strategies to enhance oncolytic viruses in cancer immunotherapy.
    Tian Y; Xie D; Yang L
    Signal Transduct Target Ther; 2022 Apr; 7(1):117. PubMed ID: 35387984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fighting Cancer with Viruses: Oncolytic Virus Therapy in China.
    Wei D; Xu J; Liu XY; Chen ZN; Bian H
    Hum Gene Ther; 2018 Feb; 29(2):151-159. PubMed ID: 29284308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.
    Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B
    Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncolytic Immunotherapy for Treatment of Cancer.
    Tsun A; Miao XN; Wang CM; Yu DC
    Adv Exp Med Biol; 2016; 909():241-83. PubMed ID: 27240460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emerging field of oncolytic virus-based cancer immunotherapy.
    Ma R; Li Z; Chiocca EA; Caligiuri MA; Yu J
    Trends Cancer; 2023 Feb; 9(2):122-139. PubMed ID: 36402738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic Viruses as an Adjunct to Immune Checkpoint Inhibition.
    Ripp J; Hentzen S; Saeed A
    Front Biosci (Landmark Ed); 2022 May; 27(5):151. PubMed ID: 35638418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Functional Assay to Determine the Capacity of Oncolytic Viruses to Induce Immunogenic Tumor Cell Death.
    Delaunay T; Achard C; Grégoire M; Tangy F; Boisgerault N; Fonteneau JF
    Methods Mol Biol; 2020; 2058():127-132. PubMed ID: 31486035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic Virotherapy: A New Paradigm in Cancer Immunotherapy.
    Volovat SR; Scripcariu DV; Vasilache IA; Stolniceanu CR; Volovat C; Augustin IG; Volovat CC; Ostafe MR; Andreea-Voichița SG; Bejusca-Vieriu T; Lungulescu CV; Sur D; Boboc D
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 64.